Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$9.95−0.62 (-5.87%)
Close on Nov 20, 2026Market cap $7.94BP/E –Yield –
Summit Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Summit Therapeutics's pe ratio was 3.5× on Jan 31, 2022, against 11.0× a year earlier. Over the last 3 years it ranged from 2.0× to 12.7×, with a median of 5.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2022 | Jan 31, 2022 | 3.5× | −0.8 |
| 2021 | Dec 31, 2021 | 4.3× | −3.2 |
| 2020 | Dec 31, 2020 | 7.5× | +4.9 |
| 2019 | Dec 31, 2019 | 2.5× | – |
See a number that looks wrong?